MRI is increasingly utilized for the diagnosis of liver disease and focal liver lesions. While liver-targeted gadolinium-based contrast agents (GBCAs) have high efficacy, they are shadowed by safety concerns regarding tissue retention. We have developed a liver-targeted manganese alternative – Mn-EOB-PC2A – that uses a liver-targeted ethoxybenzyl modified macrocyclic pyclen diacetate platform. Relaxivity measurements for Mn-EOB-PC2A suggest comparable performance to the GBCA alternatives, and in vitro characterization suggests strong uptake in hepatocytes with minimal toxicity. MRI with Mn-EOB-PC2A demonstrated strong liver-specific enhancement at a clinically relevant dose, underscoring the potential for Mn-EOB-PC2A as an alternative to traditional liver-targeted Gd-based platforms.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords